|Bid||N/A x N/A|
|Ask||N/A x N/A|
|Day's Range||N/A - N/A|
|52 Week Range||undefined - undefined|
|Beta (3Y Monthly)||N/A|
|PE Ratio (TTM)||N/A|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||N/A|
OTC PINK: ROSGF)(the "Company") announced today that the pending of merger of a subsidiary of Genoptix, Inc. with the Company has not occurred as scheduled and that Genoptix has refused to provide assurances that it intends to complete the transaction. Unless the transaction is completed by May 30, 2018, the Company intends to file for bankruptcy protection in Israel and the United States. Genoptix has asserted the existence of a "Material Adverse Effect" affecting the Company and breaches of representations and warranties, which the Company disputes.
If you are a shareholder in Rosetta Genomics Ltd’s (NASDAQ:ROSG), or are thinking about investing in the company, knowing how it contributes to the risk and reward profile of yourRead More...
PHILADELPHIA, PA and REHOVOT, ISRAEL / ACCESSWIRE / May 18, 2018 / Rosetta Genomics Ltd. (the "Company") (ROSG) announced today that on May 18, 2018, it received a decision letter from NASDAQ Stock Market ("Nasdaq") following a hearing that was held on May 17, 2018, informing the Company that the Nasdaq Hearing Panel has determined to delist the shares of the Company from the Nasdaq Stock Market and will suspend trading in those shares effective at the open of business on Tuesday, May 22, 2018. On April 16, 2018, the Nasdaq staff notified the Company that it was in violation of Listing Rule 5250(f) for failure to timely pay its annual listing fee.
PHILADELPHIA, PAand REHOVOT, ISRAEL / ACCESSWIRE / May 7, 2018 / Rosetta Genomics Ltd. (the "Company") (ROSG) announced today that on May 2, 2018, it received a "delinquency" delisting notice from NASDAQ Stock Market ("Nasdaq"). The Company has not yet filed its Form 20-F as required pursuant to Nasdaq's Listing Rule 5250(c)(2) for the period ended December 31, 2017.On May 1, 2018, the Company filed a Form 12b-25 stating that, "…the Company does not believe it will be able to file its Form 20-F within the fifteenth calendar day after its prescribed due date." Based upon this disclosure and the Company's failure to meet the terms of the Staff's extension concerning complying with Nasdaq's minimum stockholders' equity requirement pursuant to Nasdaq Listing Rule 5550(b) (the "Rule"), Nasdaq has determined that this serves as an additional basis for delisting the Company's securities from Nasdaq.
Improvement in profitability and outperformance against the industry can be important characteristics in a stock for some investors. Below, I will assess Rosetta Genomics Ltd’s (NASDAQ:ROSG) track record on aRead More...
PHILADELPHIA, PA and REHOVOT, ISRAEL / ACCESSWIRE / April 26, 2018 / Rosetta Genomics Ltd. (the "Company") (ROSG) today announced that its shareholders approved a proposed merger with a subsidiary of Genoptix, Inc. ("Genoptix") at an extraordinary general meeting of shareholders. At the closing, Rosetta will become a privately held company owned by Genoptix and its shares will cease to trade. Within five business days following the closing, the payment agent to be engaged for such purpose will provide instructions to each holder of record of Ordinary Shares of Rosetta which will explain how to surrender share certificates.